Ming-Chun Hsu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

Medicine, Dermatology, Immunology +15

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Kristian Reich, April W. Armstrong, Richard G. Langley et al. · The Lancet · 2019 · 376 citations

Medicine, Dermatology, Immunology +12

Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

Richard G. Langley, Mark Lebwohl, Gerald G. Krueger et al. · British Journal of Dermatology · 2014 · 203 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

Alexa B. Kimball, Philippe Szapary, Ulrich Mrowietz et al. · Journal of the American Academy of Dermatology · 2011 · 128 citations

Medicine, Clinical Sciences, Dermatology +11

Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

Carrie Brodmerkel, Eric Wadman, Richard G. Langley et al. · PubMed · 2013 · 69 citations

Life Sciences, Dermatology, Immunology +16